KGK Team Studying Pantethine, Cholesterol Link

LONDON, Ontario—KGK Synergize’s Contract Research Division will work with John A. Rumberger, Ph.D., M.D., on a clinical trial investigating the effect of pantethine as a dietary supplement for lipid management and heart health. Sponsored by New York-based Daiichi Fine Chemical, the supplier of Pantesin® pantethine, the randomized, double blind, placebo-controlled study will be conducted in two North American locations under the direction of Dale Wilson, M.D., KGK medical director and principal investigator for this study. Rumberger, a leading authority on cardiovascular health and current director of cardiac imaging at the Princeton Longevity Center, will consult with KGK on protocol design and comment on study findings.

“A large body of research points to Pantethine’s effectiveness in Asian and Western European populations, where oral administration of Pantethine has consistently shown an ability to favorably impact a variety of risk factors in people with hypercholesterolemia, arteriosclerosis and diabetes,” Rumberger said. “The aim of the current trial is to confirm these results in a clinical setting in North America where cardiovascular disease is the leading cause of death.”